Nathan A Pennell
Overview
Explore the profile of Nathan A Pennell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
4030
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
2.
Delasos L, Khorrami M, Viswanathan V, Jazieh K, Ding Y, Mutha P, et al.
NPJ Precis Oncol
. 2024 Dec;
8(1):290.
PMID: 39719541
Unresectable stage III NSCLC is now treated with chemoradiation (CRT) followed by immune checkpoint inhibitors (ICI). Pneumonitis, a common CRT complication, has heightened risk with ICI, potentially causing severe outcomes....
3.
Raez L, Massey A, Barker S, Peterson P, Liming K, Pennell N
Oncologist
. 2024 Oct;
29(12):1068-1078.
PMID: 39471424
Background: Selpercatinib is a selective RET inhibitor approved for treatment of RET-activated cancers. Adverse events (AEs) are manageable with dose modifications. This post hoc analysis characterized selpercatinib's clinical safety profile...
4.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2024 Oct;
635(8038):462-471.
PMID: 39385035
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of...
5.
Muthusamy B, Berktas M, Li J, Thomas D, Sun P, Taylor A, et al.
Future Oncol
. 2024 Jun;
20(28):2083-2096.
PMID: 38916211
To describe real-world biomarker testing, treatment and survival in stage IA-IIIC non-small cell lung cancer (NSCLC). Electronic records of USA-based patients in the CancerLinQ Discovery database with stage IA-IIIC NSCLC...
6.
Goldschmidt J, Annavarapu S, Venkatasetty D, Wang Y, Santorelli M, Burke T, et al.
Immunotherapy
. 2024 Mar;
16(7):453-464.
PMID: 38487917
We assessed treatment patterns and outcomes in patients with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) who initiated first-line pembrolizumab-platinum-pemetrexed (induction) in US community oncology settings. Patients initiating induction were retrospectively...
7.
8.
Muthusamy B, Pennell N
Transl Lung Cancer Res
. 2023 Aug;
12(7):1649-1651.
PMID: 37577316
No abstract available.
9.
Somasundaram E, Wadhwa R, Litzler A, Barker-Clarke R, Qi P, Videtic G, et al.
JCO Clin Cancer Inform
. 2023 Jun;
7:e2200173.
PMID: 37369090
Purpose: Improved survival prediction and risk stratification in non-small-cell lung cancer (NSCLC) would lead to better prognosis counseling, adjuvant therapy selection, and clinical trial design. We propose the persistent homology...
10.
Delasos L, Wei W, Hassan K, Pennell N, Patil P, Stevenson J
Clin Lung Cancer
. 2023 May;
24(6):e205-e213.
PMID: 37188597
Background: Often, patients with NSCLC experience recurrent/refractory (R/R) disease within 2 years of chemoradiation (CRT) and consolidative durvalumab. Despite prior immune checkpoint inhibitor exposure, immunotherapy with or without chemotherapy is...